Kochi-based investor Porinju Veliyath's journey from an investor to Equity Intelligence, his firm which managed over Rs 1,200 crore worth of portfolio.
Arvind Bothra, vice president of institutional research at Religare Capital Markets is cautious on Ranbaxy because the earnings visibility is very low and believes that the expectations of a turnaround in the US business etc are seemingly priced-in the stock.
In an interview to CNBC-TV18, technical analyst Sudarshan Sukhani, s2analytics.com said, the trend for the market next week is simple and clear. Usually when market breaks out of a long narrow trading range there is a sustainable momentum behind that break.
Drug firm Wockhardt today said it has redeemed 20.85 crore optionally convertible cumulative redeemable preference shares (OCCRPS) on November 27.